The combination of ibrutinib and rituximab demonstrates activity in first‐line follicular lymphoma

This phase 2 study evaluated the activity and safety of ibrutinib, a Bruton’s tyrosine kinase inhibitor, plus rituximab in adults with previously untreated follicular lymphoma. Patients received once‐daily ibrutinib 560 mg continuously plus once‐weekly rituximab 375 mg/m(2) for 4 weeks beginning Wee...

Descripción completa

Detalles Bibliográficos
Autores principales: Fowler, Nathan H., Nastoupil, Loretta, De Vos, Sven, Knapp, Mark, Flinn, Ian W., Chen, Robert, Advani, Ranjana H., Bhatia, Sumeet, Martin, Peter, Mena, Raul, Davis, Richard Eric, Neelapu, Sattva S., Eckert, Karl, Ping, Jerry, Co, Melannie, Beaupre, Darrin M., Neuenburg, Jutta K., Palomba, M. Lia
Formato: Online Artículo Texto
Lenguaje:English
Publicado: John Wiley and Sons Inc. 2020
Materias:
Haematological Malignancy ‐ Clinical
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7317728/
https://www.ncbi.nlm.nih.gov/pubmed/32180219
http://dx.doi.org/10.1111/bjh.16424

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7317728/
https://www.ncbi.nlm.nih.gov/pubmed/32180219
http://dx.doi.org/10.1111/bjh.16424

Ejemplares similares